COMMUNIQUÉS West-GlobeNewswire

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

13/01/2025 - 15:00

The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan. 13, 2025 (GLOBE [...]

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

13/01/2025 - 15:00

Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Achieved in [...]

VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025

13/01/2025 - 15:00

CAMPBELL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with [...]

Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference

13/01/2025 - 15:00

Reports $709 million in preliminary 1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE ® U.S. net product revenues, including $167 million in 4Q 2024 $98 million in EMPAVELI ® U.S. net product revenues, [...]

Clover Health Reports 27% Growth in Medicare Advantage Membership, Surpassing 100,000 Lives After Strong Annual Election Period

13/01/2025 - 15:00

Robust plan benefits powered member growth, mainly driven by switchers from other plans Company will focus on balancing profitability with strategic investments in growth and technology to take advantage of strong [...]

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024

13/01/2025 - 15:00

Fourth Quarter 2024 worldwide revenue of ~ $48.8 to $49.0 million representing growth of ~26% Achieved adjusted EBITDA profitability in the fourth quarter SANTA CLARA, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- SI-BONE, [...]

Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

13/01/2025 - 15:00

Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with the potential to treat well over 100 million patients CTAs [...]

Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch

13/01/2025 - 15:00

More patients treated with ZTlido ® saw either a decrease or discontinuation of opioid use compared with those treated with the 5% patch (51.9% vs. 45.5%). Of all study patients reporting a decrease in opioid use, [...]

Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment

13/01/2025 - 15:00

ATTENS (ADHD trial of external trigeminal nerve stimulation) Project , led by Professor Katya Rubia at the Institute of Psychiatry, Psychology & Neuroscience is a multicentre , double-blind, placebo-controlled [...]

ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9

13/01/2025 - 15:00

The new Express License service removes barriers to accessing this transformative gene editing technology for startups. An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio [...]

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

13/01/2025 - 15:00

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchise Biomea preparing icovamenib for late-stage clinical development 2025 corporate update to be presented at the 43 rd [...]

New Standard for Medtech Alternate Equipment Management (AEM)

13/01/2025 - 14:57

AAMI Document Clarifies Repair Requirements Arlington, VA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Alternate equipment management (AEM) plans for medical devices can create friction between original equipment manufacturers ( [...]

Novo Nordisk A/S - share repurchase programme

13/01/2025 - 14:52

Bagsværd, Denmark, 13 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April [...]

OneMedNet Regains Compliance with NASDAQ Listing Requirements

13/01/2025 - 14:50

MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World [...]

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

13/01/2025 - 14:41

TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with [...]

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

12/01/2025 - 22:00

2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year 1 Strong and Growing Demand for Galafold ® and Pombiliti ® + Opfolda ® Total Revenue Growth of 17-24% at CER Expected in 2025 >3,000 [...]

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

12/01/2025 - 18:00

New biomarkers on track for commercial launch in January 2025 Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn [...]

Mereo BioPharma Provides Update on Lead Clinical Programs

12/01/2025 - 17:05

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive [...]

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

12/01/2025 - 17:00

Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance, including Crysvita® revenue of $405 million to $410 million, and Dojolvi® revenue of $87 million to $89 million 2025 [...]